Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Role of the Blood-Brain Barrier in Multiple Sclerosis.
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K
Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.
Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
[Controlled research on multiple sclerosis treated with electroacupuncture and acupoint injection].
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.
Reduced serum orexin-A levels in autoimmune encephalitis and neuromyelitis optica patients.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
Visual Functional and Histopathological Correlation in Experimental Autoimmune Optic Neuritis.
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
The investigation of acute optic neuritis: a review and proposed protocol.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Reproductive issues in women with multiple sclerosis: ethical considerations.
Prevention and treatment of MS: studying the effects of vitamin D.
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).
Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Pages
« first
‹ previous
…
97
98
99
100
101
102
103
104
105
…
next ›
last »